# Anika Therapeutics, Inc.: financial statements, quarterly

ANIK · Nasdaq · CIK 898437 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/anik.md) · [Financials](/companies/anik/financials.md) · [Filings](/companies/anik/filings.md) · [Insiders](/companies/anik/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/anik/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [41.5](/filings/0001171843-24-005993.md) | [(2.9) d](/filings/0001171843-26-001275.md) | [29.0](/filings/0001171843-25-003019.md) | [30.7](/filings/0001171843-25-004826.md) | [29.6](/filings/0001171843-25-007032.md) | [30.6 d](/filings/0001171843-26-001275.md) | [26.2](/filings/0001171843-26-002852.md) | [28.2](/filings/0001171843-26-005012.md) | [27.8](/filings/0001171843-25-007032.md) | [30.6 d](/filings/0001171843-26-001275.md) | [29.6](/filings/0001171843-26-002852.md) | [32.6](/filings/0001171843-26-005012.md) |
| Cost of revenue | $m | [16.5](/filings/0001171843-24-005993.md) | [(8.7) d](/filings/0001171843-26-001275.md) | [10.0](/filings/0001171843-25-003019.md) | [10.2](/filings/0001171843-25-004826.md) | [10.2](/filings/0001171843-25-007032.md) | [13.5 d](/filings/0001171843-26-001275.md) | [11.5](/filings/0001171843-26-002852.md) | [13.9](/filings/0001171843-26-005012.md) | [12.2](/filings/0001171843-25-007032.md) | [11.4 d](/filings/0001171843-26-001275.md) | [10.6](/filings/0001171843-26-002852.md) | [11.4](/filings/0001171843-26-005012.md) |
| Gross profit | $m | [24.9](/filings/0001171843-24-005993.md) | [5.8 d](/filings/0001171843-26-001275.md) | [19.0](/filings/0001171843-25-003019.md) | [20.5](/filings/0001171843-25-004826.md) | [19.4](/filings/0001171843-25-007032.md) | [17.1 d](/filings/0001171843-26-001275.md) | [14.7](/filings/0001171843-26-002852.md) | [14.4](/filings/0001171843-26-005012.md) | [15.6](/filings/0001171843-25-007032.md) | [19.2 d](/filings/0001171843-26-001275.md) | [19.0](/filings/0001171843-26-002852.md) | [21.2](/filings/0001171843-26-005012.md) |
| Research and development | $m | [7.8](/filings/0001171843-24-005993.md) | [(3.3) d](/filings/0001171843-26-001275.md) | [6.4](/filings/0001171843-25-003019.md) | [6.7](/filings/0001171843-25-004826.md) | [5.9](/filings/0001171843-25-007032.md) | [6.5 d](/filings/0001171843-26-001275.md) | [6.1](/filings/0001171843-26-002852.md) | [6.3](/filings/0001171843-26-005012.md) | [6.9](/filings/0001171843-25-007032.md) | [6.5 d](/filings/0001171843-26-001275.md) | [6.7](/filings/0001171843-26-002852.md) | [7.3](/filings/0001171843-26-005012.md) |
| Selling, general and administrative | $m | [24.8](/filings/0001171843-24-005993.md) | [(15.6) d](/filings/0001171843-26-001275.md) | [15.1](/filings/0001171843-25-003019.md) | [15.6](/filings/0001171843-25-004826.md) | [13.5](/filings/0001171843-25-007032.md) | [11.3 d](/filings/0001171843-26-001275.md) | [12.9](/filings/0001171843-26-002852.md) | [12.2](/filings/0001171843-26-005012.md) | [11.9](/filings/0001171843-25-007032.md) | [12.1 d](/filings/0001171843-26-001275.md) | [17.8](/filings/0001171843-26-002852.md) | [10.9](/filings/0001171843-26-005012.md) |
| Operating income | $m | [(7.7)](/filings/0001171843-24-005993.md) | [24.7 d](/filings/0001171843-26-001275.md) | [(2.5)](/filings/0001171843-25-003019.md) | [(1.8)](/filings/0001171843-25-004826.md) | [(0.1)](/filings/0001171843-25-007032.md) | [(0.7) d](/filings/0001171843-26-001275.md) | [(4.3)](/filings/0001171843-26-002852.md) | [(4.2)](/filings/0001171843-26-005012.md) | [(3.2)](/filings/0001171843-25-007032.md) | [0.6 d](/filings/0001171843-26-001275.md) | [(5.5)](/filings/0001171843-26-002852.md) | [3.0](/filings/0001171843-26-005012.md) |
| Income tax | $m | [(0.5)](/filings/0001171843-24-005993.md) | [9.1 d](/filings/0001171843-26-001275.md) | [0.0](/filings/0001171843-25-003019.md) | [1.3](/filings/0001171843-25-004826.md) | [2.2](/filings/0001171843-25-007032.md) | [2.5 d](/filings/0001171843-26-001275.md) | [0.1](/filings/0001171843-26-002852.md) | [0.7](/filings/0001171843-26-005012.md) | [0.9](/filings/0001171843-25-007032.md) | [(1.0) d](/filings/0001171843-26-001275.md) | [0.2](/filings/0001171843-26-002852.md) | [0.1](/filings/0001171843-26-005012.md) |
| Net income | $m | [(6.6)](/filings/0001171843-24-005993.md) | [(63.0) d](/filings/0001171843-26-001275.md) | [(4.5)](/filings/0001171843-25-007032.md) | [(0.1)](/filings/0001171843-25-007032.md) | [(29.9)](/filings/0001171843-25-007032.md) | [(21.9) d](/filings/0001171843-26-001275.md) | [(4.9)](/filings/0001171843-26-005012.md) | [(4.0)](/filings/0001171843-26-005012.md) | [(2.3)](/filings/0001171843-25-007032.md) | [0.3 d](/filings/0001171843-26-001275.md) | [(5.1)](/filings/0001171843-26-005012.md) | [3.3](/filings/0001171843-26-005012.md) |
| Diluted EPS | $ per share | [(0.45)](/filings/0001171843-24-005993.md) | not reported | [(0.31)](/filings/0001171843-25-003019.md) | [0.00](/filings/0001171843-25-004826.md) | [(2.03)](/filings/0001171843-25-007032.md) | not reported | [(0.34)](/filings/0001171843-26-002852.md) | [(0.28)](/filings/0001171843-26-005012.md) | [(0.16)](/filings/0001171843-25-007032.md) | not reported | [(0.37)](/filings/0001171843-26-002852.md) | [0.24](/filings/0001171843-26-005012.md) |
| Basic EPS | $ per share | [(0.45)](/filings/0001171843-24-005993.md) | not reported | [(0.31)](/filings/0001171843-25-003019.md) | [(0.01)](/filings/0001171843-25-004826.md) | [(2.03)](/filings/0001171843-25-007032.md) | not reported | [(0.34)](/filings/0001171843-26-002852.md) | [(0.28)](/filings/0001171843-26-005012.md) | [(0.16)](/filings/0001171843-25-007032.md) | not reported | [(0.37)](/filings/0001171843-26-002852.md) | [0.25](/filings/0001171843-26-005012.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [70.7](/filings/0001171843-23-006687.md) | [68.7](/filings/0001171843-25-001486.md) | [68.6](/filings/0001171843-24-002682.md) | [62.8](/filings/0001171843-24-004615.md) | [62.4](/filings/0001171843-24-005993.md) | [55.6](/filings/0001171843-26-001275.md) | [53.4](/filings/0001171843-25-003019.md) | [53.2](/filings/0001171843-25-004826.md) | [58.0](/filings/0001171843-25-007032.md) | [57.5](/filings/0001171843-26-005012.md) | [41.0](/filings/0001171843-26-002852.md) | [38.4](/filings/0001171843-26-005012.md) |
| Current assets | $m | [157](/filings/0001171843-23-006687.md) | [163](/filings/0001171843-25-001486.md) | [159](/filings/0001171843-24-002682.md) | [155](/filings/0001171843-24-004615.md) | [136](/filings/0001171843-24-005993.md) | [114](/filings/0001171843-26-001275.md) | [103](/filings/0001171843-25-003019.md) | [99.3](/filings/0001171843-25-004826.md) | [102](/filings/0001171843-25-007032.md) | [103](/filings/0001171843-26-005012.md) | [93.6](/filings/0001171843-26-002852.md) | [99.2](/filings/0001171843-26-005012.md) |
| Total assets | $m | [328](/filings/0001171843-23-006687.md) | [271](/filings/0001171843-25-001486.md) | [264](/filings/0001171843-24-002682.md) | [263](/filings/0001171843-24-004615.md) | [231](/filings/0001171843-24-005993.md) | [203](/filings/0001171843-26-001275.md) | [191](/filings/0001171843-25-003019.md) | [188](/filings/0001171843-25-004826.md) | [189](/filings/0001171843-25-007032.md) | [190](/filings/0001171843-26-005012.md) | [179](/filings/0001171843-26-002852.md) | [183](/filings/0001171843-26-005012.md) |
| Current liabilities | $m | [28.1](/filings/0001171843-23-006687.md) | [31.1](/filings/0001171843-25-001486.md) | [28.5](/filings/0001171843-24-002682.md) | [26.1](/filings/0001171843-24-004615.md) | [25.5](/filings/0001171843-24-005993.md) | [23.3](/filings/0001171843-26-001275.md) | [17.9](/filings/0001171843-25-003019.md) | [16.1](/filings/0001171843-25-004826.md) | [19.1](/filings/0001171843-25-007032.md) | [21.9](/filings/0001171843-26-005012.md) | [21.0](/filings/0001171843-26-002852.md) | [22.1](/filings/0001171843-26-005012.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [270](/filings/0001171843-24-005993.md) | [212](/filings/0001171843-26-001275.md) | [209](/filings/0001171843-25-007032.md) | [210](/filings/0001171843-25-007032.md) | [180](/filings/0001171843-25-007032.md) | [154](/filings/0001171843-26-005012.md) | [148](/filings/0001171843-26-005012.md) | [148](/filings/0001171843-26-005012.md) | [147](/filings/0001171843-25-007032.md) | [143](/filings/0001171843-26-005012.md) | [134](/filings/0001171843-26-005012.md) | [137](/filings/0001171843-26-005012.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [6,485 d](/filings/0001171843-24-005993.md) | [3,638 d](/filings/0001171843-26-001275.md) | [(126)](/filings/0001171843-25-003019.md) | [(1,069) d](/filings/0001171843-25-004826.md) | [5,016 d](/filings/0001171843-25-007032.md) | [1,582 d](/filings/0001171843-26-001275.md) | [(130)](/filings/0001171843-26-002852.md) | [(189) d](/filings/0001171843-26-005012.md) | [6,870 d](/filings/0001171843-25-007032.md) | [4,637 d](/filings/0001171843-26-001275.md) | [(4,846)](/filings/0001171843-26-002852.md) | [(684) d](/filings/0001171843-26-005012.md) |
| Capital expenditure | $k | [741 d](/filings/0001171843-24-005993.md) | [1,840 d](/filings/0001171843-26-001275.md) | [1,808](/filings/0001171843-25-003019.md) | [3,403 d](/filings/0001171843-25-004826.md) | [1,216 d](/filings/0001171843-25-007032.md) | [1,307 d](/filings/0001171843-26-001275.md) | [2,824](/filings/0001171843-26-002852.md) | [1,467 d](/filings/0001171843-26-005012.md) | [1,887 d](/filings/0001171843-25-007032.md) | [648 d](/filings/0001171843-26-001275.md) | [1,431](/filings/0001171843-26-002852.md) | [1,449 d](/filings/0001171843-26-005012.md) |
| Share repurchases | $k | [0.0 d](/filings/0001171843-24-005993.md) | [0.0 d](/filings/0001171843-26-001275.md) | [0.0](/filings/0001171843-25-003019.md) | [1,370 d](/filings/0001171843-25-004826.md) | [3,969 d](/filings/0001171843-25-007032.md) | [5,575 d](/filings/0001171843-26-001275.md) | [3,971](/filings/0001171843-26-002852.md) | [0.0 d](/filings/0001171843-26-005012.md) | [0.0 d](/filings/0001171843-25-007032.md) | [5,514 d](/filings/0001171843-26-001275.md) | [8,690](/filings/0001171843-26-002852.md) | [853 d](/filings/0001171843-26-005012.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [14.6](/filings/0001171843-23-006687.md) | [14.7](/filings/0001171843-24-002682.md) | [14.7](/filings/0001171843-24-004615.md) | [14.6](/filings/0001171843-24-005993.md) | [14.7](/filings/0001171843-25-003019.md) | [14.9](/filings/0001171843-25-004826.md) | [14.8](/filings/0001171843-25-007032.md) | [14.3](/filings/0001171843-26-002852.md) | [14.5](/filings/0001171843-26-005012.md) | [14.4](/filings/0001171843-25-007032.md) | [13.5](/filings/0001171843-26-002852.md) | [13.7](/filings/0001171843-26-005012.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 13,382,966 at 2026-07-24, from the cover of the [10-Q filed 2026-07-29](/filings/0001171843-26-005012.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.